Equipment: NanoPET/CTIn vivo CT imaging of mouse teethSettings:- 65kV- 360 projections- 1600ms/projection- Medium zoom (resolution: 19µm)Determination of the volume of the pulp with the 3D ROI tools (InVivoScope)
Equipment: NanoPET/CTIn vivo CT imaging of a skull of mouse.
Settings: - 65kV- 360 projections- 1600ms/projection- Medium zoom (resolution: 19µm)- Acquisition time: 30min
Equipment: BioPET/CT
Protocol:- rats- Left image: iv injection of fenestra- Right image: ip injection of Iopamiro (Bracco), 0.03ml dose- CT Acq: 35kV, 200µA, 360 proj ; Binning 4, 8 images averaged/proj ; total acq time: 400sec- Image reconstrcution: 90s on a standard personal computer
Protocol:- Mouse, 125g- CT Acq: 40kV, 200µA, no contrast injected
Protocol: - Tumor cells-pancreatic Ca - Male, 47g, nude - Dose: 590µCi, 300µL, 18F-FDG - Incubation period: 47min - CT contrast: Iopamiro, 200µL, ip - CT Acq: 350µA, 45kVp, 360proj, 8 shots, Std resolution - PET Acq: Static, 40min, 400-700keVSee also MIP image
Protocol:- Tumor cells-pancreatic Ca- Male, 47g, nude- Dose: 590µCi, 300µL, 18F-FDG- Incubation period: 47min- CT contrast: Iopamiro, 200µL, ip- CT Acq: 350µA, 45kVp, 360proj, 8 shots, Std resolution- PET Acq: Static, 40min, 400-700keVSee also slices images
Protocol:- Wistar male rat, 168g- Dose: 1.15mCi (42.55MBq) of 18F-FDG- Incubation period: 49min- PET acq. time: 45min, 3 FOV, 400-700keV, 8 slices overlap- CT acq.: 150µA, 45kVp, 360°, 8 shots, 200µm resolution, 10min acq.
Protocol:- 179g rat- Active tumour on left side, inactive tumour on right side- 740µCi 18F-FDG- Whole body scan: 4 beds (5min each) ; 4 slice overlap ; repeated 3x ; 120min total acquisition- 2D-OSEM reconstruction (iterations=2, subset=16)
Protocol:- 23g Nu/Nu mouse- PMSA+ PC-3 PIP tumour on the left shoulder- PSMA- PC-3 PIP timour on the right shoulder- 200µCi 18F-DCFBC- Whole body scan: 2 beds (5min each) ; 4 slices overlap ; repeated 12x ; 120min total acquisition- 2D-OSEM reconstruction (iterations=2, subset=16)
Protocol: - 23g ApoE -/- mouse - 530µCi (19.61MBq) 18F-FDG - 45min uptake - 15min non-gated acquisition
Protocol:- 23g ApoE -/- mouse- 530µCi (19.61MBq) 18F-FDG- 45min uptake- 15min non-gated acquisition
Equipment: BioPET
Protocol: - 11w, 20.8g mouse - 22MBq (0.58mCi)- 60min uptake- 15min acquisition (250-700KeV) - Reconstruction 3D-OSEM (iteration=5, Subset=50, No AC, no gating)
Protocol:- 7w, 250g rat- 74MBq (2mCi)- 120min uptake- 30min acquisition (250-700KeV)- 3D-OSEM reconstruction (iteration=2, Subset=50)
Protocol:- 9w, 308g- 56MBq (1.5mCi) 18F-NaF- Reconstruction 3D-OSEM (iteration=5, Subset=50, No AC)- Condition not fasted- Anesthesia isoflurane 1.5%
Protocol:- 190g Wistar rat- 475µCi 18F-FDG injection- 60 min uptake- Animal sacrified- 60 min acquisition- 2D OSEM reconstructionSee also slices images
Protocol:- 190g Wistar rat- 475µCi 18F-FDG injection- 60 min uptake- Animal sacrified- 60 min acquisition- 2D OSEM reconstructionSee also MIP image
Equipment: NanoSPECT/CTSPECT/CT images acquired 2h post-injection of 99mTc-HYNIC-Spermine (0.3mCi) in a melanoma tumor-bearing mouse (scan time: ~20min). The probe was accumulated in the tumor and unspecific fixations were visible in the liver and the kidneys.For more details, see "99mTc-HYNIC-Spermine for imaging polyamine transport system-positive tumours: preclinical evaluation", Eur J Nucl Med Imaging, 2011
Equipment: NanoSPECT/CTA CT image of a mouse injected with Fenestra VC contrast agent (15ml/kg, i.v.) is presented. The whole body CT image was acquired 10 minutes post-injection in 9 minutes with 55 kvP tube voltage and 1000ms exposure time.
Equipment: NanoSPECT/CT• In this study, a new bifunctional agent was used for DOTA?conjugation of trastuzumab. The functionality of the 111In-DOTA-trastuzumab conjugate was assessed in in vitro assays prior to in vivo evaluation (affinity ~ 5x10-9 mol.L-1, immunoreactivity > 60%). • 17 days after the subcutaneous implantation of Her-2 expressing BT-474 tumors, mice were injected IV with 25 µg (13-15 MBq) 111In-DOTA-trastuzumab. SPECT images acquired 72 hours after the IV injection showed a strong uptake of the radiolabelled conjugate in the tumor, which was confirmed by ex-vivo biodistribution (tumor uptake > 60 %ID/g).• Scan times:CT : 5 minSPECT: 45 min
Images courtesy of Pharmimage, Dijon, Francewww.pharmimage.fr
'
